Data for R&D
How to maximize data’s potential in drug and device research & development.
Data for R&D, Thursday 10 October 2019
08:00
Registration & Breakfast
Plenary Keynotes
08:35
Chairperson’s opening remarks
08:40
Data innovation in the American government: how the HHS effectively leverages data, technology and innovation to improve lives
09:00
Automating data: how AI and automation will impact the use of data applied to lab interconnectivity and sample analysis
09:20
Keynote Panel
Data strategies for R&D, addressing the importance of privacy, leveraging new technology and analytics for product commercialization, and integrating data into pharma companies.
10:20
Networking Coffee Break
Oncology
Data for R&D
11:00Targeting groups of cancer genes in a pathway: how to identify driver alterations within pathways and choose a targetable alteration to optimize cancer therapy
Data for R&D
11:20Cancer data mining: how to leverage the recent influx of complex molecular data in immune-oncology to understand tumor- immune interaction, identify new targets, and develop novel biomarkers
Data for R&D
11:40Creating value through large genomic data sets: how human guided machine learning is used to analyze large patient data sets and develop novel oncology therapies
12:20
Networking Lunch
ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30 minutes – attendees can select two roundtables to attend)
13:40
Roundtable: Incentivizing orphan drug innovation: how to motivate companies to develop orphan drugs through changes to reimbursement and tax incentives
Monika Schneider, Research Associate, Margolis Center For Health Policy, Duke University
13:40
Roundtable: Microbiomes as indicators of health: how the surrounding environment can impact human health, and an examination of the data supporting this as evidence
13:40
Roundtable: Mitigating the risk of mobile healthcare
How to secure data with the influx of healthcare apps and the move to patient interaction via mobile devices by conducting more frequent HIPAA security checks and penetration-testing / vulnerability-assessments of IT systems.
13:40
Roundtable: Multidisciplinary approaches: how to apply digital data to drug discovery, use new technology for data mining, and utilize machine learning
13:40
Roundtable: The impact of safety data collection: how to treat disease and improve the quality of life for patients while properly characterizing the effects of the drug
13:40
Roundtable: Using data to develop innovative telemedicine programs: sharing ideas for the creation and implementation of telehealth programs
13:40
Roundtable:Terabytes of data is not enough: building a better biobank via data product design, analytic services, data delivery, cloud-based analytic toolkits and other means
Pricing & Reimbursement
Data for R&D
14:50Value based assessment: how Real-World Evidence (RWE) can improve estimates of actual drug use and costs, and increase transparency in health outcomes
More information soon.
Data for R&D
15:10Transforming insight access: identifying companies developing similar assets, ranking experts in the field, and visualizing trends in future impact areas to support value assessment
Networking Coffee Break
Plenary Keynotes
Data Democratization
16:50
Keynote Fireside Chat: Data democratization: how to convey the value of data sharing to the industry, patients, and clinic
Kamal Sharma, Director, Strategic Initiatives, Director, Strategic Initiatives, Data Strategy & Services, Novartis Pharmaceutical
17:50
Closing remarks followed by networking drinks reception
More information soon.
last published: 11/Oct/19 15:25
Data for R&D, Friday 11 October 2019
08:00
Registration & Breakfast
Plenary Keynotes
09:20
C-level / SVP Healthcare Panel: data strategies to lower the cost of healthcare, encouraging collaboration between entities, and integrating EMR usage for increased efficiency
Jason Johnson, Senior Vice President, Chief Health Information Officer, Dana Farber Cancer Institute
Mayur Saxena, Chief Executive Officer, Droice Labs
10:20
Networking coffee break
Rare Diseases
Data for R&D
11:00EMR: how using Electronic Medical Record data and genetic data accelerates drug discovery, development and RWE applications
Data for R&D
11:20FDA updates for rare disease data: how to approach rare disease data and make company-wide updates to improve data submission
Xin Du, Senior Vice President And Head Of Global Regulatory Affairs, Adlai Nortye Biopharma
Data for R&D
11:40Data sharing for rare diseases: assessing the importance of data sharing for rare disease product development
Data for R&D
11:40Real world data for rare diseases: how to make drug development more feasible for rare diseases and improve regulatory decision making
More information soon.
12:20
Networking Lunch
13:40
Roundtable: AI for therapeutics: how to apply automation and machine learning to treatments and encourage the use of AI beyond drug discovery
13:40
ROUNDTABLE: AI integration: how incorporating AI into all phases of drug development from target discovery, to the recovery of failed projects is transforming pharma
13:40
Roundtable: Computational molecular dynamics: small molecule data approaches for modifying drugs and identifying targets
13:40
Roundtable: Data to Eliminate Health Disparities
Addressing the need for diversity in clinical trials and treatment by strategizing locations of research centers and clinics, creating accessible physician support, and using data to target individuals for outreach
13:40
Roundtable: Genomics in drug discovery: how to expedite the drug development through genomics and structural/cultural changes
13:40
Roundtable: Strategic data presentations for government support
How to engage government officials by shifting from the use of quantitative data (hard numbers) to qualitative data (telling the patient story) in your presentation.
Eve Bukowski, Vice President, Patient Advocacy, Education and Outreach, California Life Sciences Association - CLSA
13:40
Roundtable: Using data for clinical collaboration: how to accelerate research by encouraging collaboration between industry and patient advocates and by sharing data for use in clinical trial design
Kerry Leeson-Beevers, National Development Manager, Alstrom Syndrome U.K.
ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30 minutes – attendees can select two roundtables to attend)
Non-Clinical Data
15:30
End of Conference
last published: 11/Oct/19 15:25
Contact us
To sponsor or exhibit contact:
André Singer
t/ 646.619.1797
andre.singer@terrapinn.com
To speak:
Anna Bagley
t/ 646 619-1803
anna.bagley@terrapinn.com
Organiser
